AstraZeneca aims to transform cancer treatment and advance clinical practice with data presented at ESMO 2020
Pivotal overall survival data confirm benefit of Lynparza use in advanced prostate cancer Data in early treatment of lung cancer highlight potential to improve patient outcomes in curative-intent settings with Tagrisso and ImfinziAstraZeneca will present new developments in pursuit of its ambition to eliminate cancer as a cause of death at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, 19 to 21 September. AstraZeneca medicines and pipeline molecules feature in 114 abstracts at ESMO, a record for the Company, including 20 oral presentations and two Presidential